Prescribe With Confidence
At Mantara, we use state-of-the-art DNA testing technology and the latest pharmacogenomic evidence to support your medical decision-making.
The Science Behind Our Test
The information provided in a Mantara PGx Test report is based on sound guidance provided by the top pharmacogenomic experts in the UK and Europe. Using the same protocol and recommendations as the UPGx study published in The Lancet in 2023, the information provided in our DNA reports can improve your confidence to prescribe medications more accurately within approved guidelines.
World-Class DNA Testing
Our partner laboratory, based in Germany, is a world-class specialist provider of genetic laboratory services. They use high-quality genetic analysers operated by highly experienced geneticists and laboratory scientists. They produce reliable DNA genotyping suitable for the very specific requirements of pharmacogenomic reporting. You can be confident of the quality of the reports your patients share with you. Our software is fully validated and accredited by the College of American Pathologists and was used in the European UPGx project.
High Quality Reporting
We work in partnership with bio.logis to provide clear interpretation of a patient’s genotype using their CE and UKCA-marked medical device software, developed to provide the reporting for UPGx, a major European study (more on this below). This sets out clearly whether there is any genetic component to be taken into account when prescribing, alongside all other factors.
Many medicine SmPCs already include guidance on recommended actions when genetic information is available. With a Mantara® PGx report, you will now have access to that information, increasing your confidence in making the most appropriate prescription choice.
The Basis of Our Recommendations
Our reports only carry fully ‘actionable’ advice from the Dutch Pharmacogenetics Working Group (DPWG) and as shown in the Prepare Study which included the University of Liverpool, ensuring you can rely on good quality information to help guide your prescription choice. Other products which are available on the market also include a number of ‘informational’ recommendations which have not so far been determined by DPWG to carry sufficient evidence to become ‘actionable’. We do not yet include those medicines.
Recent Research: the UPGx Trial
The Ubiquitous Pharmacogenomics (UPGx) study, the largest of its kind in Europe (including in the UK), has successfully concluded with around 7,000 patients participating. Its primary objective was to assess the cost-effectiveness and improved patient outcomes via pre-emptive genotyping of a comprehensive panel of pharmacogenomic markers.
The findings, published in The Lancet, revealed that personalised medication dosages informed by patients' genetic profiles led to a 30% reduction in serious side effects. Overseen by prominent European pharmacogenetics experts, including the NHS Chair of Pharmacogenetics at the University of Liverpool, the study has set a precedent for integrating pharmacogenomics into clinical practice.
The success of UPGx, particularly the implementation of a 'DNA medication pass', underscores the potential for significant advancements in personalised medicine, signalling a move toward safer, more effective treatments for patients. This trial represents a substantial leap forward in healthcare, promising to shape future research and implementation in the field of pharmacogenomics.
Our test uses the same lab partner and guidelines as those outlined in the UPGx study.
Would You Like to Get Involved?
If you are a healthcare professional who would like to get involved with pharmacogenomics, either to provide the Mantara PGx DNA Test to your patients or to take part in research, please don’t hesitate to get in touch. We would be delighted to speak to you.
Exclusive Partnership With World-Class Laboratory
Comprehensive Test Shows Results for 12 Genes
CE and UKCA Marked PGx DNA Test Kits
To find out more about pharmacogenomics, head over to our resource centre where you’ll find further research, the latest news coverage and educational material.